From bench to bedside: translating novel-target ADCs against treatment-resistant tumors

Lauren Coyle, Launch Commissioning Editor, Bioconjugate Insights, speaks with Valerie Vanhooren, Co-Founder and CEO, Ona Therapeutics, about translating first-in-class ADCs from bench to bedside, including target validation, resistance biology, linker-payload strategy, and the company culture that sustains high-risk, high-gain drug development.